by Admin Neo Lumina | Oct 18, 2023 | News
First patient enrolled in psilocybin trial for demoralisation Diamond Therapeutics has announced that the first patient has been enrolled in its FDA-authorised UAB-Diamond trial evaluating low-dose psilocybin in patients with demoralization. The trial is enrolling 60...
by Admin Neo Lumina | Oct 17, 2023 | News
A New Frontier For Psilocybin Therapy? Standardized but NOT Synthetic If you wanted to do clinical trials for psilocybin, you generally have two options: synthetic psilocybin (which has it’s downsides) or whole dried mushrooms (also, has downsides). But what if...
by Admin Neo Lumina | Oct 17, 2023 | News
Clinical trial investigating psilocybin for opioid addiction approved Health Canada has given Filament Health authorisation to carry out a Phase 2 clinical trial investigating PEX010 – the company’s botanical psilocybin drug candidate – for the treatment of opioid use...
by Admin Neo Lumina | Oct 15, 2023 | News
European psychedelic initiative aims to impact education and regulation A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and boost EU-funded research on...
by Admin Neo Lumina | Oct 4, 2023 | News
Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats Psilocybin (a classic serotonergic psychedelic drug) has received appraisal for use in...
by Admin Neo Lumina | Sep 25, 2023 | News
Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggests In a new exploratory phase II clinical trial, a single dose of psilocybin, when used as an adjunct to ongoing SSRI treatment and combined with supportive...
